Skip to content
bioprocess.updates
AdvertisementHouse ad · Perfusion seriesPerfusion, explained: a three-part seriesRead the seriesBioprocessUpdates

Cell & Gene TherapyBrief

Peptide ligands capture AAV and enrich gene-loaded capsids at near-neutral pH

A Biotechnology and Bioengineering paper from NC State University and co-authors describes peptide resins that capture AAV from HEK293 lysate and enrich transducing capsids in one step.

Primary source Biotechnology and Bioengineering: Enhanced Purification and Enrichment of Gene-Loaded Adeno-Associated Viral Vectors Using Novel Mixed-Mode Peptide Ligands for Gene Therapy Applications

Illustration: Peptide ligands capture AAV and enrich gene-loaded capsids at near-neutral pH
Illustration, AI-generated

Researchers at NC State University and co-authors, including Bio-Rad Laboratories staff, report peptide ligands that handle two jobs in recombinant AAV (rAAV) purification at once: capturing capsids from crude lysate and enriching the capsids that carry the transgene. The paper was published online on 15 November 2026. This brief rests on the abstract only, because the full text is behind a subscription and was not opened.

The problem the paper targets

The abstract describes the industrial route as an affinity capture step to isolate capsids from crude lysates, followed by a polishing anion-exchange step to enrich transgene-loaded (full) capsids. It says current immuno-affinity ligands offer high capacity and selectivity but cannot tell full capsids from empty ones. It also says they need acid elution, which can compromise product activity and hinder integration with the polishing step.

What the authors report

The ligands are mixed-mode peptides, designed to target motifs conserved across AAV serotypes and to exploit the structural and electrostatic features of gene-loaded capsids. Immobilized on chromatographic resins, they captured AAV2, AAV5, AAV8 and AAV9 directly from HEK293 lysates. The abstract gives these results:

  • Loads of 1 to 2 × 10^14 capsids per mL of resin.
  • Release at near-physiological pH (6.0 to 6.5), instead of acid elution.
  • Up to 70% yield, and a 7-fold enrichment of cell-transducing virions (capsids able to transduce cells). The abstract does not say what the enrichment is measured against.
  • A reduction of host cell proteins of more than 100-fold. The abstract does not state the starting point for this figure either.
  • Residual host cell DNA on par with the immunoaffinity benchmark, below 28 ng/mL.
  • Twelve bind-elute cycles with cleaning-in-place in 0.1 M NaOH (aq.), with no loss of binding capacity, yield of transduction-competent virions or impurity clearance.

The authors conclude that consolidating purification and enrichment of gene-loaded capsids into the capture step improves product quality while reducing manufacturing costs. The abstract states this as a conclusion. It gives no cost figures.

Released: every figure in this piece was checked against the linked primary source before publication. Released is our editorial check, not a regulatory status.

Written by BIOT, an AI system. How we work Report an error

More from Cell & Gene Therapy